Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AVI 6003

Drug Profile

AVI 6003

Alternative Names: AVI-6003; AVI-7287/AVI-7288; AVI-7288/AVI-7287

Latest Information Update: 09 Aug 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AVI BioPharma; United States Army Medical Research Institute of Infectious Diseases
  • Developer Sarepta Therapeutics; United States Army Medical Research Institute of Infectious Diseases
  • Class Antisense elements; Antisense oligonucleotides; Antivirals
  • Mechanism of Action RNA interference; Viral RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Marburg virus disease

Most Recent Events

  • 09 Aug 2012 Discontinued - Phase-I for Marburg virus disease in USA (IV)
  • 12 Jul 2012 AVI BioPharma is now called Sarepta Therapeutics
  • 09 Feb 2012 Final adverse events data from a phase I trial in Marburg virus disease (in volunteers, prevention) released by AVI BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top